01—Abstract
Summary
Summary of the 10-Q filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported a net loss of $169.6 milliona for the three months ended March 31, 2025, compared with a net loss of $36.2 million in the prior-year period.
Total revenues, net were $116.6 millionb, down from $211.1 million, as license and services revenue fell to $79.9 million from $211.1 million. Net product revenue from Attruby in the U.S. was $36.7 million, and the filing notes that the $75.0 million regulatory milestone from Bayer, recognized in license and services revenue, was received in April 2025. Research and development expense decreased to $111.4 million from $141.0 million, while selling, general and administrative expense rose to $106.4 million from $65.8 million, mainly reflecting commercial activities for Attruby.
During the quarter the company issued $575.0 millionc of 1.75% convertible senior notes due 2031 and used the proceeds to fully repay the $450.0 million principal term loan under its Amended Financing Agreement, along with $48.3 million to repurchase 1,405,411 shares of common stock. Cash and cash equivalents declined to $540.6 million from $681.1 million at December 31, 2024. Total stockholders' deficit was $1.64 billion, and total liabilities were $2.52 billion.
Management states it expects its cash, cash equivalents and restricted cash to fund operations for at least the next 12 months, and it expects continued operating and net losses for at least the next several years. The filing also notes that Attruby received FDA approval on November 22, 2024, Beyonttra was approved by the European Commission on February 10, 2025 and in Japan on March 27, 2025, and that the company is pursuing three late-stage candidates: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9.
02—Key points
Key Highlights
- Net loss widened to $169.6 million from $36.2 million in the prior-year quarter.
- Total revenues, net were $116.6 million, down from $211.1 million, driven by lower license and services revenue ($79.9 million vs. $211.1 million).
- Net product revenue from Attruby in the U.S. reached $36.7 million in the first quarter of 2025, its first quarter of commercial sales.
- Selling, general and administrative expense rose to $106.4 million from $65.8 million, mainly for Attruby commercial activities.
- Issued $575.0 million of 2031 convertible notes and fully repaid the $450.0 million term loan under the Amended Financing Agreement.
- Cash and cash equivalents fell to $540.6 million from $681.1 million at December 31, 2024; the company expects this to fund operations for at least the next 12 months.
- Total stockholders' deficit was $1.64 billion at March 31, 2025.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q1 FY2025, BridgeBio Pharma lost $1.44.
- Revenue$116.6M100.0%
- Cost of revenue−$2.6M2.3%
- Gross profit$114.0M97.7%
- Operating costs−$218.4M187.2%
- Operating income−$104.4M89.5%
- Interest, other & tax−$63.0M54.1%
- Net income−$167.4M143.5%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 29, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $116.63M$211.12M | −44.8% |
| Cost of Revenue | $2.64M$598K | +341.3% |
| Gross Profit | $113.99M$210.52M | −45.9% |
| R&D Expenses | $111.43M$140.97M | −21.0% |
| SG&A Expenses | $106.36M$65.81M | +61.6% |
| Operating Expenses | $221.00M$210.78M | +4.9% |
| Operating Income | -$104.37M$343K | −30529.2% |
| Interest Expense | $9.59M$8.57M | +11.9% |
| Net Income | -$167.42M-$35.22M | −375.4% |
| EPS (Basic) | $-0.88$-0.20 | −340.0% |
| EPS (Diluted) | $-0.88$-0.20 | −340.0% |
| Shares Outstanding (Basic) | 190.15M178.71M | +6.4% |
| Shares Outstanding (Diluted) | 190.15M178.71M | +6.4% |
05—Questions
Frequently Asked Questions
How much revenue did BridgeBio generate from Attruby, and what drove the decline in total revenue?
The filing reports net product revenue of $36.7 million from the commercial sale of Attruby in the U.S. Total revenues, net decreased to $116.6 million from $211.1 million, because license and services revenue fell to $79.9 million from $211.1 million. The prior-year period included $201.2 million from upfront license fees under the Bayer and KKC agreements, while the current period mainly reflects a $75.0 million regulatory milestone from Bayer.
Why did the net loss increase compared with the prior year?
Net loss was $169.6 million versus $36.2 million. The main drivers were lower license and services revenue, higher selling, general and administrative expense of $106.4 million (up from $65.8 million), interest expense of $42.1 million (up from $23.5 million), and a $15.6 million net loss from equity method investments. Research and development expense partially offset these, declining to $111.4 million from $141.0 million.
What changes did the company make to its debt in the first quarter?
On February 28, 2025, BridgeBio issued $575.0 million of 1.75% convertible senior notes due 2031 and received net proceeds of approximately $563.0 million. It used those proceeds to fully repay the Amended Financing Agreement, which totaled $467.0 million including $450.0 million of principal, and recognized a $21.2 million loss on extinguishment of debt. The filing also notes that about $48.3 million was used to repurchase 1,405,411 shares of common stock.
How much liquidity does the company have, and what does management expect?
Cash and cash equivalents were $540.6 million at March 31, 2025, compared with $681.1 million at December 31, 2024. Management expects its cash, cash equivalents and restricted cash to fund operations for at least the next 12 months based on current plans, but notes it may need additional funding sooner if plans change and that future financing may not be available on acceptable terms. It also expects operating and net losses to continue for at least the next several years.
What regulatory and pipeline milestones are described in the filing?
The filing states that Attruby received FDA approval on November 22, 2024, that the European Commission approved Beyonttra for ATTR-CM on February 10, 2025, and that Japan's Ministry of Health, Labour and Welfare approved Beyonttra on March 27, 2025. The company lists three late-stage product candidates: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9. It also reports a restructuring in which it ceased development of BBP-631 for congenital adrenal hyperplasia.
06—Continue